 BOSTON and JERUSALEM, June 23, 2021 GLOBE NEWSWIRE -- Entera Bio Ltd. NASDAQ: ENTX, a leader in the development of orally delivered large molecule and biologic therapeutics, announced the final 6-month bone mineral density BMD results from the completed Phase 2 clinical trial of EB613 for the treatment of osteoporosis. EB613 is an oral formulation of human parathyroid hormone 1-34, or PTH, positioned to be the first oral bone building anabolic product to treat osteoporosis patients. Currently, fewer than 5 of osteoporosis patients on any form of therapy are treated with an injectable anabolic agent, widely accepted as the most effective form of treatment1. The Phase 2 clinical trial of EB613 was a 6-month double blind, dose-ranging, placebo-controlled study in 161 postmenopausal female subjects with osteoporosis, or with low bone mineral density BMD. This study was conducted at four leading medical centers in Israel to evaluate the safety and efficacy of varying doses of EB613. All lab tests including biomarkers and safety monitoring were performed at a certified central laboratory, and BMD data from clinical sites was analyzed at an independent certified global imaging center. 